Impaired Alanine Transport or Exposure to d-Cycloserine Increases the Susceptibility of MRSA to β-lactam Antibiotics.
Alanine
/ metabolism
Animals
Anti-Bacterial Agents
/ pharmacology
Antimetabolites
/ pharmacology
Bacterial Proteins
/ genetics
Bacteriological Techniques
Biological Transport
Cycloserine
/ pharmacology
Female
Gene Expression Regulation, Bacterial
/ drug effects
Humans
Methicillin Resistance
/ drug effects
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Mice
Mutation
Polysaccharides
/ chemistry
Staphylococcal Infections
/ drug therapy
beta-Lactams
/ pharmacology
MRSA
alanine transport
antibiotic resistance
d-cycloserine
β-lactam resistance
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
02 03 2020
02 03 2020
Historique:
received:
09
07
2019
accepted:
14
10
2019
pubmed:
20
10
2019
medline:
26
11
2020
entrez:
20
10
2019
Statut:
ppublish
Résumé
Prolonging the clinical effectiveness of β-lactams, which remain first-line antibiotics for many infections, is an important part of efforts to address antimicrobial resistance. We report here that inactivation of the predicted d-cycloserine (DCS) transporter gene cycA resensitized methicillin-resistant Staphylococcus aureus (MRSA) to β-lactam antibiotics. The cycA mutation also resulted in hypersusceptibility to DCS, an alanine analogue antibiotic that inhibits alanine racemase and d-alanine ligase required for d-alanine incorporation into cell wall peptidoglycan. Alanine transport was impaired in the cycA mutant, and this correlated with increased susceptibility to oxacillin and DCS. The cycA mutation or exposure to DCS were both associated with the accumulation of muropeptides with tripeptide stems lacking the terminal d-ala-d-ala and reduced peptidoglycan cross-linking, prompting us to investigate synergism between β-lactams and DCS. DCS resensitized MRSA to β-lactams in vitro and significantly enhanced MRSA eradication by oxacillin in a mouse bacteremia model. These findings reveal alanine transport as a new therapeutic target to enhance the susceptibility of MRSA to β-lactam antibiotics.
Identifiants
pubmed: 31628459
pii: 5599748
doi: 10.1093/infdis/jiz542
pmc: PMC7050987
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antimetabolites
0
Bacterial Proteins
0
Polysaccharides
0
beta-Lactams
0
Cycloserine
95IK5KI84Z
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000-1016Subventions
Organisme : Medical Research Council
ID : MR/M020045/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R002592/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P01 AI083211
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
PLoS Pathog. 2012;8(4):e1002626
pubmed: 22496652
Nat Genet. 2016 May;48(5):544-51
pubmed: 27064254
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6091-9
pubmed: 27480853
J Bacteriol. 1965 Nov;90(5):1238-50
pubmed: 5321479
J Biol Chem. 1997 Nov 14;272(46):29053-9
pubmed: 9360979
PLoS One. 2012;7(8):e43467
pubmed: 22912881
mBio. 2019 Apr 30;10(2):
pubmed: 31040245
J Bacteriol. 2013 Apr;195(7):1389-99
pubmed: 23316042
Neurochem Int. 2007 Jul-Sep;51(2-4):233-6
pubmed: 17662507
J Infect Dis. 2017 Jan 1;215(1):80-87
pubmed: 28077586
Methods Mol Biol. 2016;1440:11-27
pubmed: 27311661
Trials. 2016 Mar 31;17:170
pubmed: 27029920
J Bacteriol. 2006 Apr;188(7):2543-53
pubmed: 16547042
PLoS One. 2013 Aug 27;8(8):e73512
pubmed: 24013956
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2639-51
pubmed: 26856828
J Biol Chem. 1992 Jun 5;267(16):11248-54
pubmed: 1597460
J Bacteriol. 2010 Aug;192(15):3883-92
pubmed: 20525824
J Bacteriol. 2014 Feb;196(4):894-902
pubmed: 24336937
Clin Infect Dis. 2016 Jan 15;62(2):173-180
pubmed: 26349552
Antimicrob Agents Chemother. 1987 Dec;31(12):1982-8
pubmed: 3439805
Mutat Res. 2006 Mar 20;595(1-2):184-90
pubmed: 16376388
Ann N Y Acad Sci. 1971 Jun 11;182:258-66
pubmed: 5285290
Nat Commun. 2017 Dec 5;8(1):1939
pubmed: 29208891
J Bacteriol. 1971 Mar;105(3):1028-35
pubmed: 4926674
mBio. 2013 Feb 12;4(1):e00537-12
pubmed: 23404398
PLoS One. 2013 Apr 23;8(4):e61083
pubmed: 23637786
J Antimicrob Chemother. 1997 May;39 Suppl A:47-51
pubmed: 9511062
Antimicrob Agents Chemother. 2012 Jan;56(1):579-81
pubmed: 21986827
Nat Chem Biol. 2007 Sep;3(9):541-8
pubmed: 17710100
Clin Microbiol Rev. 1997 Oct;10(4):781-91
pubmed: 9336672
J Med Microbiol. 1991 Mar;34(3):143-7
pubmed: 2010904
J Bacteriol. 2002 Aug;184(16):4400-8
pubmed: 12142410
Sci Rep. 2014 Dec 16;4:7494
pubmed: 25510564
Antimicrob Agents Chemother. 2002 Oct;46(10):3151-5
pubmed: 12234837
Cell Host Microbe. 2018 Aug 8;24(2):261-270.e4
pubmed: 30057172
Antimicrob Agents Chemother. 1976 Feb;9(2):347-9
pubmed: 773296
J Bacteriol. 1972 Aug;111(2):622-4
pubmed: 4559741
mBio. 2017 Feb 14;8(1):
pubmed: 28196956
Microb Drug Resist. 2013 Jun;19(3):153-9
pubmed: 23659600
Microb Drug Resist. 2003 Fall;9(3):231-41
pubmed: 12959401
Infect Immun. 2010 May;78(5):1873-83
pubmed: 20212088
J Antibiot (Tokyo). 2017 Jul;70(8):907-910
pubmed: 28588223